A combination of ticlopidine and aspirin has been accepted as the standard
antithrombotic regimen after coronary stenting. However, ticlopidine poses
serious side effects such as neutropenia or thrombocytopenia. Cilostazol, a
cyclic adenosine monophosphate phosphodiesterase inhibitor, is a novel ant
iplatelet agent with vasodilatory properties. We compared the efficacy and
safety of cilostarol plus aspirin (C+A) with ticlopidine plus aspirin (T+A)
in elective coronary stenting. Three hundred patients were randomly assign
ed to receive C+A or T+A 2 days before stenting. The primary end point was
a composite of angiographic stent thrombosis, or major cardiac events (deat
h, myocardial infarction, bypass surgery, repeat intervention) at 30 days.
The secondary end points were bleeding vascular complications, neutropenia,
thrombocytopenia, or side effects requiring discontinuation of the drugs a
t 30 days. The primary end point was reached in 1.4% in the C+A group and 2
.0% in the T+A group (p = 1.0). The rate of bleeding vascular complications
was 1.4% in the C+A group and 2.0% in the T+A group (p = 1.0). The rate of
drug-related side effects was not statistically different between the 2 gr
oups but slightly higher in the T+A group than in the C+A group (2.7% vs 0.
7%, p = 0.37). However, neutropenia was seen in 2 patients only in the T+A
group. As a poststenting antithrombotic, C+A is as effective as T+A in prev
enting major cardiac events including stent thrombosis, and safer in that i
t does not cause neutropenia despite the fact that there is no statistical
difference in the incidence of adverse effects and complications. (C) 1999
by Excerpta Medico, Inc.